EC Approves Parsabiv for Treatment of Secondary Hyperparathyroidism

The EC has granted marketing authorization for Parsabiv for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic kidney disease.

This first time approval is based on three Phase III studies, all of which met their primary endpoints.

Parsabiv was superior to cinacalcet for the secondary endpoints of a proportion of patients achieving greater than 30 percent and greater than 50 percent reduction in mean parathyroid hormone during the efficacy assessment phase compared with baseline.